Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

Mary Eapen, Joseph Antin, Jakub Tolar, Sally Arai, Mitchell Horwitz, Jainqun Kou, Eric Leifere, John M. McCarty, Ryotaro Nakamura, Michael A. Pulsipher, Mary M. Horowitz, H Joachim Deeg

Blood (2023) 142 (Supplement 1): 235.

https://doi.org/10.1182/blood-2023-178093

Published: 2023

Journal Articles

The DNA Sensor AIM2 Determines B Cell Fate after BCR Activation in Chronic Graft-Vs-Host Disease

Fahmin Basher, Jonathan Visentin, Wei Jia, Jonathan C Poe, Christina Sofian, Hsuan Su, Sonali Bracken, Rachel Dicioccio, Itaevia Curry-Chisolm, Vincent T. Ho, Vanja Sisirak, Mitchell Horwitz, Nelson J. Chao, Stefanie Sarantopoulos

Blood (2023) 142 (Supplement 1): 2050.

https://doi.org/10.1182/blood-2023-188072

Published: 2023

Journal Articles

Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program

Mitchell Horwitz, Stephanie B. Tsai, Andrew R. Rezvani, Richard T Maziarz, Uri Goshen, Stuart Levy, Aurelie Schwarzbach, Roei D. Mazor, Patrick J. Stiff, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 6894.

https://doi.org/10.1182/blood-2023-181167

Published: 2023

Journal Articles

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Sarah Nikiforow, Mitchell Horwitz, John M. McCarty, Anum Abbas, James M. Coghill, Jenny Stanton, Julie Ma, Spyridoula Vasileiou, Sarah Gilmore, Bhagirathbhai Dholaria, Rabi Hanna, Randy Taplitz, Rajat Bansal

Blood (2023) 142 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2023-189708

Published: 2023

Journal Articles

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Jakub Tolar, MD, PhD, H. Joachim Deeg, M.D., Sally Arai, MD, Mitchell Horwitz, MD, Joseph H. Antin, MD, John M. McCarty, MD, Roberta H. Adams, MD, Mary Eapen, MBBS, Marian Ewell, ScD, Eric Leifer, PhD, Iris Gersten, MS, Shelly L Carter, ScD, Mary M. Horowitz, MD, Dennis L Confer, MD, Ryotaro Nakamura, MD, Michael Pulsipher, MD, Nancy L DiFronzo, PhD, Paolo Anderlini, MD

Blood (2011) 118 (21): 3009.

https://doi.org/10.1182/blood.V118.21.3009.3009

Published: 2011

Journal Articles

Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.

Blood (2009) 114 (22): 3320.

https://doi.org/10.1182/blood.V114.22.3320.3320

Published: 2009

Journal Articles

Use of Aldehyde Dehydrogenase Content to Predict Dominating Cord in Double Cord Blood Transplant.

Kristin M Page, MD, Tracy Gentry, Kevin Shoulars, PhD, Mitchell Horwitz, MD, Nicholas Herrmann, Norin Meadows, Brittney Philipps, Andrew Balber, PhD, Joanne Kurtzberg, MD

Blood (2009) 114 (22): 2155.

https://doi.org/10.1182/blood.V114.22.2155.2155

Published: 2009

Journal Articles

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, Ivana N. M. Micallef, Patrick J. Stiff, Jonathan L. Kaufman, Richard T. Maziarz, Chitra Hosing, Stefan Früehauf, Mitchell Horwitz, Dennis Cooper, Gary Bridger, Gary Calandra, for the 3102 Investigators

Blood (2009) 113 (23): 5720–5726.

https://doi.org/10.1182/blood-2008-08-174946

Published: 2009

Journal Articles

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, Jon P Gockerman, Louis F Diehl, MD, Carlos de Castro, III, MD, Joseph O Moore, Gwynn D Long, Mitchell Horwitz, MD, John Chute, MD, Keith M Sullivan, MD, Rachel Neuwirth, Patricia H Davis, Linda M. Sutton, Russell D Anderson, Nelson Chao, David A. Rizzieri, MD

Blood (2008) 112 (11): 3325.

https://doi.org/10.1182/blood.V112.11.3325.3325

Published: 2008

Journal Articles

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

David A. Rizzieri, MD, Robert Storms, Ph.D, Daniel Nikcevich, MD, PhD, Bercedis Peterson, Ph.D, Debashish Misra, MD, Christine Apple, Megan Baker, Cristina Gasparetto, MD, Mitchell Horwitz, MD, John Chute, MD, Ashley Morris, PharmD., Nelson J. Chao, MD

Blood (2008) 112 (11): 342.

https://doi.org/10.1182/blood.V112.11.342.342

Published: 2008

Journal Articles

Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality

Mitchell Horwitz, MD, John Chute, MD, Cristina Gasparetto, MD, Gwynn Long, MD, David Rizzieri, MD, Keith Sullivan, MD, Jackie McPherson, Nelson Chao, MD

Blood (2008) 112 (11): 4403.

https://doi.org/10.1182/blood.V112.11.4403.4403

Published: 2008

Journal Articles

Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.

Mitchell Horwitz, MD, John Chute, MD, Cristina Gasparetto, MD, Gwynn Long, MD, David Rizzieri, MD, Ashley Morris, PharmD, Jackie McPherson, Keith Sullivan, MD, Nelson Chao, MD

Blood (2007) 110 (11): 2007.

https://doi.org/10.1182/blood.V110.11.2007.2007

Published: 2007

Journal Articles

Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.

Mitchell Horwitz, MD, David Rizzieri, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Ashley Morris, PharmD, Keith Sullivan, MD, John Chute, MD, Dawn Marshall, Nelson Chao, MD

Blood (2006) 108 (11): 5399.

https://doi.org/10.1182/blood.V108.11.5399.5399

Published: 2006

Journal Articles

Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.

David A. Rizzieri, MD, Liang Piu Koh, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Jerald Z. Gong, MD, Anand S. Lagoo, MD, Donna Niedzwiecki, PhD, Keith M. Sullivan, MD, John Chute, MD, Mitchell Horwitz, MD, Morris Ashley, PharmD, Nelson J. Chao, MD

Blood (2005) 106 (11): 2036.

https://doi.org/10.1182/blood.V106.11.2036.2036

Published: 2005

Journal Articles

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Debashish Misra, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis Diehl, MD, Carlos de Castro, MD, Yiping Yang, MD, Cristina Gasparetto, MD, Amy Abernathy, MD, Mitchell Horwitz, MD, Gwynn D. Long, MD, John Chute, MD, Bercedis Peterson, Ph.D, Nelson J. Chao, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 4623.

https://doi.org/10.1182/blood.V106.11.4623.4623

Published: 2005

Journal Articles

Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.

David A. Rizzieri, MD, Liang Piu Koh, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Keith M. Sullivan, MD, Mitchell Horwitz, MD, John Chute, MD, Jerald Z. Gong, MD, Anand S. Lagoo, MD, Donna Niedzwiecki, PhD, Cong Xiao Lu, MD, Dawn Marshall, BS, Jeanette M. Dowell, MS, Nelson J. Chao, MD

Blood (2005) 106 (11): 2896.

https://doi.org/10.1182/blood.V106.11.2896.2896

Published: 2005

Journal Articles

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, George P. Keogh, MD, Jon P. Gockerman, MD, Mitchell Horwitz, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Louis Diehl, MD, Patty Davis, RN, Nelson Chao, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 5181.

https://doi.org/10.1182/blood.V106.11.5181.5181

Published: 2005

Journal Articles

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Sam O. Wanko, MD, Jon P. Gockerman, M.D, Joseph O. Moore, M.D, Carlos de Castro, M.D, Louis Diehl, M.D, Robert Pronitz, M.D, Cristina Gasparetto, M.D, John Chute, M.D, Mitchell Horwitz, M.D, Ashley Morris, Pharm.D, Francis Ali-Osman, PhD, Arati Rao, M.D, Donna Niedzweicki, PhD, Gwynn D. Long, M.D, Nelson J. Chao, M.D, David A. Rizzieri, M.D

Blood (2005) 106 (11): 5501.

https://doi.org/10.1182/blood.V106.11.5501.5501

Published: 2005

Journal Articles

Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

Liang-Piu Koh, MRCP, Jon P. Gockerman, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Donna Niedzwiecki, PhD, Jon Edwards, MD, Leonard Prosnitz, MD, Mitchell Horwitz, MD, Jon Chute, MD, Ashley Morris, Pharm D, Martha Lassiter, Jennifer Loftis, Patty Davis, Nelson J. Chao, MD, David A. Rizzieri, MD

Blood (2004) 104 (11): 913.

https://doi.org/10.1182/blood.V104.11.913.913

Published: 2004

NARROW

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

The DNA Sensor AIM2 Determines B Cell Fate after BCR Activation in Chronic Graft-Vs-Host Disease

Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.

Use of Aldehyde Dehydrogenase Content to Predict Dominating Cord in Double Cord Blood Transplant.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality

Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.

Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.

Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only